Ron Bose

CIViC: A knowledgebase for expert-crowdsourcing the clinical interpretation of variants in cancer

Obi L. Griffith, Steven J. M. Jones, Benjamin M. Good, 2016, bioRxiv.

Phosphoproteomic analysis of Her2/neu signaling and inhibition.

Ron Bose, Akhilesh Pandey, Balamurugan Periaswamy, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data

Ron Bose, Li-Wei Chang, Matthew J. Ellis, 2013, PloS one.

Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Li Ding, Ron Bose, Wei Shen, 2013, Cancer discovery.

Inhibition of the EGF Receptor by Binding to an Activating Kinase Domain Interface

Ron Bose, John Kuriyan, Philip A. Cole, 2007, Nature.

Quantitative Proteomics with siRNA Screening Identifies Novel Mechanisms of Trastuzumab Resistance in HER2 Amplified Breast Cancers*

Ron Bose, Ilan Vidavsky, R. Bose, 2012, Molecular & Cellular Proteomics.

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.

Li Ding, Joshua F. McMichael, Ron Bose, 2013, Cell reports.

Unsupervised detection of cancer driver mutations with parsimony-guided learning

S Joshua Swamidass, Ron Bose, S. Joshua Swamidass, 2016, Nature Genetics.

HER2 activating mutations are targets for colorectal cancer treatment.

Ron Bose, Wei Shen, Naveen Jain, 2015, Cancer discovery.

Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers

Li Ding, Malachi Griffith, Ron Bose, 2012, Cell.

Mechanism of activation and inhibition of the HER4/ErbB4 kinase.

Ron Bose, Ashutosh Pal, Sudeep Banjade, 2008, Structure.